Company Overview
Utah Medical Products, Inc. operates within the healthcare sector as a manufacturer and distributor of specialized medical devices designed for global healthcare applications. The company's product portfolio focuses on critical care tools, specifically offering fetal monitoring accessories, vacuum-assisted delivery systems, labor and delivery instruments, DISPOSA-HOOD infant respiratory hoods, and DELTRAN PLUS blood pressure monitoring systems. As of the latest available data, the company holds a market capitalization of $197.15M and reports an annual revenue of $38.52M TTM, employing a workforce of 140 individuals to support its operations. These valuation and revenue metrics indicate that Utah Medical Products, Inc. functions as a small-cap entity with a relatively modest revenue footprint compared to large-cap healthcare conglomerates. The specific concentration in medical instruments and supplies suggests a business model reliant on steady demand for essential hospital equipment rather than discretionary consumer goods. The low employee count relative to the revenue base implies a highly efficient operational structure or a business model that relies heavily on third-party manufacturing or distribution partnerships.
Financial Health
The company reported a trailing twelve-month revenue of $38.52M, generating a net income of $11.29M and an EBITDA of $15.71M. The significant gap between the $38.52M revenue and the $11.29M net income reveals a cost structure that retains approximately 29.3% of sales as profit after all expenses, taxes, and interest are accounted for. The free cash flow stands at $11.13M, which indicates a strong ability to generate cash from operations after capital expenditures, providing substantial financial flexibility for debt reduction, share buybacks, or potential acquisitions. The company maintains a highly robust balance sheet with $85.76M in cash assets against a negligible debt load of $285,000, resulting in a debt-to-equity ratio of 0.24. This disparity between total cash and total debt demonstrates an extremely conservative financial posture with minimal leverage risk. Liquidity is exceptionally high, evidenced by a current ratio of 37.62, which suggests the company possesses more than thirty-seven times the current assets necessary to cover its short-term liabilities. Return on equity is recorded at 9.5%, while return on assets sits at 6.5%, metrics that reflect moderate management effectiveness in generating returns on the capital invested by shareholders and asset base.
Valuation Assessment
The trailing twelve-month P/E ratio is 17.63, while the forward P/E is listed as N/A, implying that analysts or the market currently lack consensus on future earnings growth projections or expect earnings to remain stable. The price-to-book ratio is 1.64, indicating that the market values the company at 64% above its tangible book value, suggesting a premium assigned to its intangible assets or brand reputation. Alternative valuation metrics include a price-to-sales ratio of 5.12 and an EV/EBITDA of 7.04, which provide context for the company's valuation relative to its revenue generation and operational earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $68.71 and a 52-week low of $51.26; without a specific current price to calculate the exact percentage, the trading range defines the recent volatility boundaries for the equity. The beta value of 0.32 indicates that the stock exhibits significantly lower price volatility than the broader market, moving only about one-third as much as the overall index. This low beta characteristic is typical for small-cap companies in stable utility-like sectors such as medical supplies, offering potential downside protection during market downturns.
Growth & Income
Year-over-year revenue growth is -1.2%, while earnings growth is -6.4%, indicating that earnings are contracting at a faster rate than revenue and that the company is currently experiencing a decline in profitability. The company is a dividend payer with a dividend yield of 2.0% and a payout ratio of 35.2%, which suggests that the dividend is highly sustainable given that the company pays out less than half of its earnings to shareholders. The low payout ratio leaves ample room for earnings to decline temporarily without forcing a cut to the dividend, providing income stability for holders. The overall growth and income profile is characterized by a mature, declining revenue trajectory supported by a conservative balance sheet and a modest but reliable income stream rather than capital appreciation driven by rapid expansion.